Literature DB >> 3425027

Modification of glycosylation by tunicamycin treatment inhibits lectin-mediated adhesion of Streptococcus pneumoniae to various tissues.

G Pulverer1, J Beuth, H L Ko, J Sölter, G Uhlenbruck.   

Abstract

Oligosaccharide moieties of cell surface glycoconjugates are thought to be involved in recognition events associated with infectious diseases. Treatment of Streptococcus pneumoniae (which exhibits well defined surface lectins) with subinhibitory concentrations of the antibiotic tunicamycin was found to block the protein glycosylation of the bacterial surfaces. Since bacterial lectins (adhesins) are in most cases glycoproteins and play an important role in the organ specificity of infectious diseases, adhesion of Streptococcus pneumoniae to frozen sections of lung, meninges and kidney (from Balb/c-mice) was almost totally lacking after inhibition of the biosynthesis of N-linked carbohydrate chains which are important for an adequate lectin function. Chemiluminescence measurements of human granulocyte stimulation yielded results suggesting a great importance of lectin-carbohydrate interactions in this process, too. These experimental data indicate that the presence of specific cell surface carbohydrates is required for a successful completion of the adhesion phase of pathogenic bacteria in infectious diseases and for the induction of granulocyte stimulation.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3425027     DOI: 10.1016/s0176-6724(87)80027-5

Source DB:  PubMed          Journal:  Zentralbl Bakteriol Mikrobiol Hyg A        ISSN: 0176-6724


  2 in total

1.  The role of staphylococcal lectins in human granulocyte stimulation.

Authors:  J Beuth; H L Ko; G Pulverer
Journal:  Infection       Date:  1988       Impact factor: 3.553

2.  Rapid identification of fibronectin, vitronectin, laminin, and collagen cell surface binding proteins on coagulase-negative staphylococci by particle agglutination assays.

Authors:  M Paulsson; A Ljungh; T Wadström
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.